Commentary Among the numerous potential adverse effects of antiepileptic drug (AED) therapy, few give more pause than the risk of severe hypersensitivity reactions. Indeed, hypersensitivity reactions ranging from a benign rash to severe dermatologic reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been associated with several commonly used AEDs including carbamazepine, lamotrigine and phenytoin (1). These hypersensitivity reactions typically occur within the first 8 weeks of treatment, and clinically involve a triad of rash, fever, and organ involvement. It is well recognized that the clinical consequences of these dermatologic reactions can be severe, with the mortality rate from SJS being about 1 to 3 percent, and TEN being 30%. While at one time considered to be unpredictable, more recent studies have uncovered genetic markers such as specific alleles of human leukocyte antigens (HLA), as possible predictors of an individual's susceptibility to severe dermatological reactions. Since first being recognized in Han Chinese (2), HLA B*1502 allele has been associated with a significantly increased risk of SJS and TEN in certain ethnic groups, including Han Chinese, Malay, and Thai who receive carbamazepine. Similarly, phenytoin-associated
IMPORTANCE: The antiepileptic drug phenytoin can cause cutaneous adverse reactions, ranging from maculopapular exanthema to severe cutaneous adverse reactions, which include drug reactions with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis. The pharmacogenomic basis of phenytoinrelated severe cutaneous adverse reactions remains unknown. OBJECTIVE: To investigate the genetic factors associated with phenytoin-related severe cutaneous adverse reactions. DESIGN, SETTING, AND PARTICIPANTS: Case-control study conducted in 2002-2014 among 105 cases with phenytoin-related severe cutaneous adverse reactions (n=61 Stevens-Johnson syndrome/toxic epidermal necrolysis and n=44 drug reactions with eosinophilia and systemic symptoms), 78 cases with maculopapular exanthema, 130 phenytoin-tolerant control participants, and 3655 population controls from Taiwan, Japan, and Malaysia. A genome-wide association study (GWAS), direct sequencing of the associated loci, and replication analysis were conducted using the samples from Taiwan. The initial GWAS included samples of 60 cases with phenytoin-related severe cutaneous adverse reactions and 412 population controls from Taiwan. The results were validated in (1) 30 cases with severe cutaneous adverse reactions and 130 phenytoin-tolerant controls from Taiwan, (2) 9 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and 2869 population controls from Japan, and (3) 6 cases and 374 population controls from Malaysia. MAIN OUTCOMES AND MEASURES: Specific genetic factors associated with phenytoin-related severe cutaneous adverse reactions. RESULTS: The GWAS discovered a cluster of 16 singlenucleotide polymorphisms in CYP2C genes at 10q23.33 that reached genome-wide significance. Direct sequencing of CYP2C identified missense variant rs1057910 (CYP2C9*3) that showed significant association with phenytoin-related severe cutaneous adverse reactions (odds ratio, 12; 95% CI, 6.6-20; P=1.1 × 10 −17 ). The statistically significant association between CYP2C9*3 and phenytoin-related severe cutaneous adverse reactions was observed in additional samples from Taiwan, Japan, and Malaysia. A meta-analysis using the data from the 3 populations showed an overall odds ratio of 11 (95% CI, 6.2-18; z=8.58; P < .00001) for CYP2C9*3 association with phenytoin-related severe cutaneous adverse reactions. Delayed clearance of plasma phenytoin was detected in patients with severe cutaneous adverse reactions, especially CYP2C9*3 carriers, providing a functional link of the associated variants to the disease. CONCLUSIONS AND RELEVANCE: This study identified CYP2C variants, including CYP2C9*3, known to reduce drug clearance, as important genetic factors associated with phenytoin-related severe cutaneous adverse reactions.
Phenytoin Hypersensitivity: It's Time for Some Individuality
severe dermatological reactions have also been linked to this HLA allele, but the association is much weaker (3) .
Given that genotyping for this HLA allele may provide some insight as to an individual patients risk for developing either SJS or TEN from carbamazepine, screening patients at higher risk is well worth considering and, in fact, may be associated with reduced incidence of this adverse reaction (4). Whether similar genomic screening strategies are worthwhile in patients receiving phenytoin, however, is less clear. Surely, there must be some pharmacogenomic mechanism involved. Perhaps other aspects of phenytoin pharmacology are involved?
It is well recognized that phenytoin displays complex pharmacokinetics. It is extensively metabolized by both cytochrome P450 2C19 (CYP2C19), and CYP2C9. Metabolism to the inactive metabolite HPPH is mediated primarily via CYP2C9. The gene encoding this CYP isozyme is highly polymorphic, with at least 50 known alleles (5) . Patients with the CYP2C9*1 allele are considered a normal metabolizer, while CYP2C9*2 and CYP2C9*3 alleles are associated with decreased enzyme function, and their frequencies differ among differing racial and ethnic populations (6) . Since the CYP2C9*3 variant has been associated with a marked reduction in phenytoin systemic clearance, it stands to reason that exposure to "usual" doses of the AED in patients with the defective copy of the CYP isozyme may be at greater risk for adverse, or toxic effects, possibly through formation of a reactive metabolite. An interesting question, therefore, is do patients who have displayed severe hypersensitivity reactions to phenytoin have other pharmacogenomic characteristics that might put them at risk?
In a genome-wide association study (GWAS), Chung and colleagues evaluated 168 patients with verified phenytoinrelated severe dermatological reactions including SJS, TEN, and drug reactions with eosinophilia and systemic symptoms (DRESS), and compared them to 130 patients who had received phenytoin for at least 3 months with no evidence of adverse effects (phenytoin tolerant), as well as 412 healthy controls. Samples were drawn from patients from Taiwan, Japan, and Malaysia. Plasma phenytoin samples obtained prior to discontinuation in the severe cutaneous reaction group, as well as phenytoin tolerant group, were also analyzed.
In this analysis, 10 single nucleotide polymorphisms (SNPs) were identified. These SNPs while common in patients with severe cutaneous reactions, are rare in the population from Taiwan and in Han Chinese. When comparing the severe cutaneous reaction group to phenytoin-tolerant controls, CYP2C9*3 was significantly associated with severe reactions in Taiwanese, Japanese, and Malaysians. While no overall association was seen between phenytoin severe cutaneous reactions and HLA-A, or HLA-B*1502, looking at just those patients with SJS-TEN, addition of HLA-B*1502 to CYP2C9*3 improved sensitivity by 62%.
How then can we explain this, and moreover, are these findings of clinical importance? In addition to the GWAS analysis, Chung and colleagues also looked at phenytoin plasma concentrations immediately prior to drug discontinuation in the SJS-TEN group as well as the phenytoin tolerant patients. They found that phenytoin concentrations were significantly higher than in the control group. Furthermore, patients with CYP2C9*3 who experienced severe cutaneous reactions had significantly higher phenytoin concentrations as compared to those not carrying this allele.
Taken together, these findings suggest an interesting, and rather logical, interplay between phenytoin pharmacokinetics and immunogenicity. Drugs themselves are typically not immunogenic. Rather, a drug may be metabolized to a reactive intermediate molecule, and it is this species that can bind to a high-molecular weight protein and initiate a hypersensitivity response. This suggests that a drug such as phenytoin, when given to a patient with "defective" metabolism, may be forced down an alternate metabolic pathway, forming a reactive metabolite. A similar, yet subtly different observation has been made with anti-tuberculosis drug induced maculopapular eruptions. In a study of Korean patients receiving standard anti-tubercular treatment with isoniazid, rifampin, ethambutol, and pyrazinamide, drug-associated maculopapular eruptions were significantly associated with CYP2C9-1565 C>T, CYP2C19 W212X, and CYP2C9-CYP2C19 haplotype [T-A-T-C]. Interestingly, CYP2C9*3 was not associated with dermatological reactions in these patients (7) .
How then can we incorporate this information into practice? While we have known for some time that patients with HLA-B*1502 are at increased risk for potentially fatal hypersensitivity reactions, it would appear that this might be a bit too one-dimensional. It would seem that in select patients, there might be a perfect storm of altered drug metabolism and immunogenicity. It would clearly seem prudent to prospectively alter phenytoin dosing in patients with CYP2C9*3 genotype and to avoid the drug altogether in patients who are both HLA-B*1502 carriers and CYP2C9 poor metabolizers (5) . Unfortunately, while this might represent optimal care, how often is genotyping actually done in epilepsy practice? It is more likely that we only discover these clinically meaningful pharmacogenomic variants after the fact. Clearly, the absence of HLA-B*1502 does not guarantee that a patient will not develop SJS or TEN from phenytoin, nor does its presence ensure that this serious adverse reaction will occur.
There would now seem to be compelling evidence that to optimize AED therapy, clinicians should consider incorporating the principles of precision medicine into practice. Recently, the White House announced a research initiative designed to accelerate incorporation of precision medicine, a concept that involves incorporating individual variability into both prevention and treatment strategies (http://www.whitehouse. gov/precisionmedicine). While oncology might well present the most logical early opportunities for enhancing health outcomes from adoption of precision medicine (8), perhaps the time has finally come for the incorporation of individualized genomic approaches to therapeutic decision making in epilepsy pharmacotherapy as well.
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